#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3400	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2257	273.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1731	1731	T	345	T	210	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3400	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2257	273.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1465	1465	C	405	C	251	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6146	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3538	309.1	0	.	n	.	0	A9G	SNP	9	9	A	362	362	G	320	G	214	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6146	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3538	309.1	0	.	n	.	0	T695C	SNP	695	695	T	1048	1048	C	407	C	248	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6146	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3538	309.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2324	2324	C	292	C	184	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6146	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3538	309.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2950	2950	T	305	T	181	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6146	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3538	309.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2398	2398	A	327	A	201	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	176	folP	855	855	99.77	folP.l15.c4.ctg.1	1546	20.6	1	SNP	p	R229S	1	.	.	685	687	AGC	1125	1127	AGC	41;41;41	A;G;C	26;24;25	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	590	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3406	30.3	0	.	p	.	0	T243I	NONSYN	727	729	ACA	994	996	ATA	47;44;38	A;T;A	31;27;23	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	590	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3406	30.3	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1015	1017	ATA	37;37;37	A;T;A	23;23;22	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	590	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3406	30.3	1	SNP	p	S91F	0	.	.	271	273	TCC	538	540	TCC	50;51;49	T;C;C	29;31;30	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	590	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3406	30.3	1	SNP	p	D95N	0	.	.	283	285	GAC	550	552	GAC	52;52;52	G;A;C	30;30;30	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	590	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3406	30.3	1	SNP	p	D95G	0	.	.	283	285	GAC	550	552	GAC	52;52;52	G;A;C	30;30;30	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	176	mtrR	633	633	99.69	mtrR.l15.c4.ctg.1	1234	29.2	0	.	p	.	0	P191fs	FSHIFT	571	571	C	809	809	C	45	C	28	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	176	mtrR	633	633	99.69	mtrR.l15.c4.ctg.1	1234	29.2	1	SNP	p	G45D	0	.	.	133	135	GGC	370	372	GGC	48;49;47	G;G;C	30;31;31	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	130	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	867	26.6	0	.	n	.	0	.206T	INS	206	206	T	487	487	T	45	T	31	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	498	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3380	25.6	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1858	1860	GCC	37;37;36	G;C;C	26;26;24	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	498	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3380	25.6	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1900	1902	GCA	33;33;35	G;C;A	22;21;23	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	498	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3380	25.6	1	SNP	p	D86N	0	.	.	256	258	GAC	853	855	GAC	31;31;33	G;A;C	20;19;22	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	498	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3380	25.6	1	SNP	p	S87R	0	.	.	259	261	AGT	856	858	AGT	32;32;32	A;G;T	22;22;23	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	498	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3380	25.6	1	SNP	p	S87W	0	.	.	259	261	AGT	856	858	AGT	32;32;32	A;G;T	22;22;23	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	498	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3380	25.6	1	SNP	p	S87I	0	.	.	259	261	AGT	856	858	AGT	32;32;32	A;G;T	22;22;23	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	498	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3380	25.6	1	SNP	p	S88P	0	.	.	262	264	TCC	859	861	TCC	32;32;32	T;C;C	22;22;22	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_W_01411c	parE.WHO_W_01411c	1	1	27	470	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2483	34.2	1	SNP	p	G410V	0	.	.	1228	1230	GGT	1535	1537	GGT	38;38;38	G;G;T,G	25;25;20,1	parE.WHO_W_01411c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	626	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2340	44.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1215	1217	GCA	80;80;80	G;C;A	49;47;47	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	626	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2340	44.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1218	1220	ATC	80;80;80	A;T;C	48;48;47	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	626	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2340	44.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1230	1232	GTG	79;80;80	G;T;G	48;47;45	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	626	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2340	44.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1230	1232	GTG	79;80;80	G;T;G	48;47;45	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	626	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2340	44.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1734	1736	ACC	19;19;19	A;C;C	11;13;13	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	626	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2340	44.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1788	1790	GCG	25;26;26	G;C;G	17;17;17	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	626	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2340	44.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1788	1790	GCG	25;26;26	G;C;G	17;17;17	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	626	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2340	44.7	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1911	1913	GGT	41;43;43	G;G;T	27;27;28	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	626	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2340	44.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1920	1922	GGC	43;43;43	G;G;C	29;29;28	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	626	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2340	44.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1938	1940	CCG	44;44;44	C;C;G	24;28;25	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1084	ponA	2397	2397	99.96	ponA.l6.c17.ctg.1	3630	50.5	1	SNP	p	L421P	0	.	.	1261	1263	CTG	2077	2079	CTG	48;48;50	C,T;T;G	28,1;30;30	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	298	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1987	27.8	0	.	p	.	0	S22G	NONSYN	64	66	AGC	380	382	GGC	37;37;38	G;G;C	24;25;24	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	298	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1987	27.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	562	562	C	21	C	14	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	T18M	NONSYN	52	54	ACG	245	247	ATG	40;39;41	A;T;G	23;22;23	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	E48G	NONSYN	142	144	GAA	335	337	GGA	28;28;28	G;G;A	18;19;19	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	V75I	NONSYN	223	225	GTT	416	418	ATT	29;29;27	A;T;T	20;21;20	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	T89S	NONSYN	265	267	ACC	458	460	AGC	25;25;24	A;G;C	17;16;17	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	V98I	NONSYN	292	294	GTC	485	487	ATC	16;16;16	A;T;C	12;10;11	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	.	MULTIPLE	358	359	AA	550	551	CG	13;13	C;G	8;8	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	.	MULTIPLE	361	362	GA	553	555	CAG	13;13;13	C;A;G	7;8;8	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	N122K	NONSYN	364	366	AAC	557	559	AAA	13;13;15	A;A;A	9;7;9	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	584	586	TAT	18;18;18	T;A;T	11;9;10	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	N134K	NONSYN	400	402	AAT	593	595	AAG	18;18;18	A;A;G	12;12;12	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	V135F	NONSYN	403	405	GTG	596	598	TTT	18;18;18	T;T;T	12;11;12	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	G140K	NONSYN	418	420	GGA	611	613	AAA	18;18;18	A;A;A	11;12;12	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	K143E	NONSYN	427	429	AAA	620	622	GAA	17;19;19	G;A;A	11;12;11	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	V151A	NONSYN	451	453	GTA	644	646	GCA	19;19;19	G;C;A	11;12;11	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	T213S	NONSYN	637	639	ACA	830	832	TCA	29;31;31	T;C;A	19;20;19	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	950	952	CAA	28;28;28	C;A;A	18;17;18	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	.	INDELS	760	762	ACA	954	958	ATCAA	28;27;27;27;27	A;T;C;A;A	16;16;16;16;17	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	.	INDELS	763	764	TG	961	963	AGT	27;27;27	A;G;T	16;16;17	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	A257D	NONSYN	769	771	GCT	968	970	GAT	29;29;29	G;A;T	17;16;16	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	T269S	NONSYN	805	807	ACC	1004	1006	AGC	30;30;30	A;G;C	16;16;18	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1076	1078	AGT	36;38;36	A;G;T	22;23;21	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1082	1084	GAC	37;37;36	G;A;C	21;20;22	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1085	1087	TAC	36;33;35	T;A;C	22;20;21	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	1	SNP	p	G120K	1	.	.	358	360	AAG	550	552	CGG	13;13;13	C;G;G	8;8;7	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	1	SNP	p	A121D	1	.	.	361	363	GAC	553	556	CGC	13;13;13	C;G;C	7;8;7	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	214	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	1440	25.5	1	SNP	p	D121N	0	.	.	361	363	GAC	553	556	CGC	13;13;13	C;G;C	7;8;7	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	1620	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4862	61.0	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1992	1994	CAT	89;89;89	C;A;T	56;55;55	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	164	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1087	27.8	1	SNP	p	V57M	1	.	.	169	171	ATG	493	495	ATG	47;47;47	A;T;G	31;31;31	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
